An interview with Andrew Schwartz, Group Managing Director and Chief Investment Officer of Qualitas.
Copyright 2020 – Finance News Network
Source: Finance News Network
23 June 2020 - Renergen Limited (ASX:RLT) Managing Director Stefano Marani talks about the significance of the company's marketing and distribution agreement with Total South Africa for LNG from Phase 1 of its project.
Read More08 Jun 2021 - Danakali Limited (ASX:DKM) Executive Chairman Seamus Cornelius discusses the company's Colluli project, including financing and economics, and the positive impact of the project on the region.
Read More2 Dec 2019 - DomaCom Limited (ASX:DCL) CEO Arthur Naoumidis talks about a year of significant progress with regulators, the company's capital raising to accelerate marketing and FUM and the tailwinds making fractional investment attractive.
Read More01 Jul 2021 - SUDA Pharmaceuticals Limited (ASX:SUD) CEO & Managing Director Dr Michael Baker discusses the company's acquisition of the invariant natural killer T (iNKT) cell therapy platform from Imperial College London.
Read More04 Jul 2022 - Magnetite Mines Limited (ASX:MGT) new board member Simon Wandke discusses his background, what he will bring to the company and the company's outlook.
Read More27 Sep 2021 - LBT Innovations Limited (ASX:LBT) CEO and Managing Director Brent Barnes discusses the appointment of a US distributor for the company's APAS Independence instrument.
Read More24 Oct 2019 - BOTTY Limited Founder & CEO, Cary Gee, talks about his Conversational Commerce solution for merchants and how it leverages existing social messaging platforms to create an integrated customer engagement, analytics, payment and delivery solution.
Read More25 Nov 2022 - BluGlass Limited (ASX:BLG) President Jim Haden discusses achieving a key reliability milestone for the company's laser diodes.
Read More26 Aug 2024 - BluGlass Limited (ASX:BLG) CEO Jim Haden discusses the company's record quarter, IP deals, customer engagement and the upcoming Semiconductor Australia conference.
Read More31 Mar 2021 - Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q) CEO and Managing Director James Graham talks about progress with the company's lead anti-infective candidate Recce 327, its expanding portfolio of synthetic anti-infectives targeting viral pathogens and a broad range of bacteria, clinical trial results and priorities for 2021.
Read More
